| Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control C Pawlyn, MD Bright, AF Buros, CK Stein, Z Walters, LI Aronson, ... Blood cancer journal 7 (3), e549-e549, 2017 | 113 | 2017 |
| 8-Substituted Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase Inhibitors V Bavetsias, RM Lanigan, GF Ruda, B Atrash, MG McLaughlin, A Tumber, ... Journal of medicinal chemistry 59 (4), 1388-1409, 2016 | 99 | 2016 |
| JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells ZS Walters, B Villarejo-Balcells, D Olmos, TWS Buist, E Missiaglia, ... Oncogene 33 (9), 1148-1157, 2014 | 98 | 2014 |
| Antitumor activity of sustained N-myc reduction in rhabdomyosarcomas and transcriptional block by antigene therapy R Tonelli, A McIntyre, C Camerin, ZS Walters, K Di Leo, J Selfe, S Purgato, ... Clinical Cancer Research 18 (3), 796-807, 2012 | 89 | 2012 |
| The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx) R Ciarapica, M De Salvo, E Carcarino, G Bracaglia, L Adesso, ... Oncogene 33 (32), 4173-4184, 2014 | 73 | 2014 |
| MicroRNA and gene co-expression networks characterize biological and clinical behavior of rhabdomyosarcomas E Missiaglia, CJ Shepherd, E Aladowicz, D Olmos, J Selfe, G Pierron, ... Cancer letters 385, 251-260, 2017 | 32 | 2017 |
| The long non-coding RNA MYCNOS-01 regulates MYCN protein levels and affects growth of MYCN-amplified rhabdomyosarcoma and neuroblastoma cells EM O’Brien, JL Selfe, AS Martins, ZS Walters, JM Shipley BMC cancer 18, 1-13, 2018 | 29 | 2018 |
| Epigenetic targets in synovial sarcoma: a mini-review R Hale, S Sandakly, J Shipley, Z Walters Frontiers in Oncology 9, 1078, 2019 | 27 | 2019 |
| Phosphodiesterase type 5 inhibitors enhance chemotherapy in preclinical models of esophageal adenocarcinoma by targeting cancer-associated fibroblasts BP Sharpe, A Hayden, A Manousopoulou, A Cowie, RC Walker, ... Cell Reports Medicine 3 (6), 2022 | 12 | 2022 |
| Genomic analysis of response to neoadjuvant chemotherapy in esophageal adenocarcinoma F Izadi, BP Sharpe, SP Breininger, M Secrier, J Gibson, RC Walker, ... Cancers 13 (14), 3394, 2021 | 11 | 2021 |
| NKCC1 (SLC12a2) induces a secondary axis in Xenopus laevis embryos independently of its co‐transporter function ZS Walters, KE Haworth, BV Latinkic The Journal of Physiology 587 (3), 521-529, 2009 | 11 | 2009 |
| Pathogenic KDM5B variants in the context of developmental disorders J Harrington, G Wheway, S Willaime-Morawek, J Gibson, ZS Walters Biochimica et Biophysica Acta (BBA)-Gene Regulatory Mechanisms 1865 (5), 194848, 2022 | 7 | 2022 |
| FGF7–FGFR2 autocrine signaling increases growth and chemoresistance of fusion‐positive rhabdomyosarcomas CI Milton, J Selfe, E Aladowicz, SYK Man, C Bernauer, E Missiaglia, ... Molecular oncology 16 (6), 1272-1289, 2022 | 6 | 2022 |
| Role for the Histone Demethylase KDM4B in Rhabdomyosarcoma via CDK6 and CCNA2: Compensation by KDM4A and Apoptotic Response of Targeting Both KDM4B and KDM4A ZS Walters, E Aladowicz, B Villarejo-Balcells, G Nugent, JL Selfe, P Eve, ... Cancers 13 (7), 1734, 2021 | 6 | 2021 |
| Targeting EZH2 for the treatment of soft tissue sarcomas M Karolak, I Tracy, J Shipley, ZS Walters J. Cancer Metastasis Treat 7, 15, 2021 | 5 | 2021 |
| Targeting EZH2 in neuroblastoma J Gao, C Fosbrook, J Gibson, T Underwood, J Gray, Z Walters Cancer Treatment Reviews, 102600, 2023 | 4 | 2023 |
| Inhibition of the epigenetic modifier EZH2 upregulates cell cycle control genes to inhibit myeloma cell growth and overcome high-risk disease features C Pawlyn, M Bright, A Buros, CK Stein, Z Walters, L Aronson, F Mirabella, ... Blood 128 (22), 3289, 2016 | 3 | 2016 |
| Machine learning to predict curative multidisciplinary team treatment decisions in oesophageal cancer N Thavanesan, I Bodala, Z Walters, S Ramchurn, TJ Underwood, ... European Journal of Surgical Oncology 49 (11), 106986, 2023 | 1 | 2023 |
| Pharmacological EZH2 inhibition combined with retinoic acid treatment promotes differentiation and apoptosis in rhabdomyosarcoma cells E O’Brien, C Tse, I Tracy, I Reddin, J Selfe, J Gibson, W Tapper, ... Clinical Epigenetics 15 (1), 167, 2023 | 1 | 2023 |
| Combination EZH2 inhibition and retinoic acid treatment promotes differentiation and apoptosis in rhabdomyosarcoma cells E O’Brien, C Tse, I Tracy, I Reddin, J Selfe, J Gibson, W Tapper, ... bioRxiv, 2023.06. 12.544568, 2023 | 1 | 2023 |
Bissan Al-LazikaniProfessor, Genomic Medicine; Director Therapeutics Data ScienceVerified email at mdanderson.org
